Edwards Life Sciences Corp. (EW): Today's Featured Health Services Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Edwards Life ( EW) pushed the Health Services industry higher today making it today's featured health services winner. The industry as a whole closed the day down 0.8%. By the end of trading, Edwards Life rose $1.09 (1.3%) to $87.75 on average volume. Throughout the day, 796,319 shares of Edwards Life exchanged hands as compared to its average daily volume of one million shares. The stock ranged in a price between $85.83-$88.46 after having opened the day at $86.39 as compared to the previous trading day's close of $86.66. Other companies within the Health Services industry that increased today were: TearLab Corpoartion ( TEAR), up 8.5%, Enzo Biochem ( ENZ), up 7.8%, Celsion Corporation ( CLSN), up 7%, and Cutera ( CUTR), up 7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases or critically ill patients worldwide. Edwards Life has a market cap of $10.12 billion and is part of the health care sector. The company has a P/E ratio of 38.5, above the S&P 500 P/E ratio of 17.7. Shares are up 24% year to date as of the close of trading on Monday. Currently there are eight analysts that rate Edwards Life a buy, one analyst rates it a sell, and seven rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, BG Medicine ( BGMD), down 9.3%, MAKO Surgical Corporation ( MAKO), down 9.1%, LCA-Vision ( LCAV), down 8.6%, and Urologix ( ULGX), down 7.8%, were all laggards within the health services industry with Aetna ( AET) being today's health services industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Edwards Lifesciences: Cramer's Top Takeaways

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Edwards Lifesciences Is Not Skipping A Beat

Canaccord Says Edwards Lifesciences Is Its Favorite Med Tech Stock